New target therapies in advanced pancreatic cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Cascinu, S ^a,b   Verdecchia, L ^a,b   Valeri, N ^a,b   Berardi, R ^a,b   Scartozzi, M ^a,b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

COX 2 inhibitor; EGFR inhibitor; Farnesyl transferase inhibitor; Pancreatic cancer

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; BORTEZOMIB; CANERTINIB; CELECOXIB; CETUXIMAB; CI 779; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; I KAPPA B; LONAFARNIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MATUZUMAB; PACLITAXEL; PELITINIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; ROFECOXIB; TANOMASTAT; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARCINOGENESIS; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE THERAPY; HEADACHE; HUMAN; HYPOKALEMIA; LIVER DYSFUNCTION; MUSCULOSKELETAL DISEASE; NEUTROPENIA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; FARNESYLTRANSTRANSFERASE; GENE TARGETING; HUMANS; METALLOPROTEASES; NF-KAPPA B; PANCREATIC NEOPLASMS; PROTEASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745602251     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj971     Document Type: Review

References (42)

1. Michaud DS. Epidemiology of pancreatic cancer. Minerva Chir 2004; 59: 99-111.
2. Rasmussen HS, McCann P. Matrix Metalloproteinase Inhibition as a novel anticancer strategy: A review with special focus on Batimastat and Marimastat. Pharmacol Ther 1997; 75: 69-75.
3. Bloomston M, Zervos EE, Rosemurgy AS. Matrix Metalloproteinases and their role in pancreatic cancer: A review of preclinical studies and clinical trials. Ann Surg Oncology 2002; 9(7): 668-674.
4. Bramhall SR, Neoptolemos JP, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997; 182: 347-55.
5. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-193.
6. Evans JD, Stark A, Johnson CD et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer 2001; 85: 1865-70.
7. Moore M, Hamm J, Eisenberg P et al. A comparison between gemcitabine and the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2000; 19: 240a.
8. Bramhall SR, Rosemurgy A, Brown PD et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J Clin Oncol 2001; 19: 3447-55.
9. Saad ED, Hoff PM. Molecular-targeted agents in pancreatic cancer. Cancer Control 2004; 11: 32-38.
10. Gress TM, Muller-Pillasch F, Lerch MM et al. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407-13.
11. Kollmannsberger C, Peters HD, Fink U. Chemotherapy in advanced pancreatic adenocarcinoma. Cancer Treat Rev 1998; 24; 133-156.
12. Van Custem E, van de Velde, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22: 1430-1438.
13. Molina MA, Sitja-Arnau M, Lemoine MG et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59: 4356-4362.
14. Okami J, Yamamoto H, Fujiwara Y et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999; 5: 2018-2024.
15. Xiong HQ, Du M, Wolff RA et al. Pharmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer. Proc Am Soc Clin Oncol 2002; 448.
16. Smith SE, Burris HA, Loehrer PJ et al. Preliminary report of a phase II trial of gemcitabine combined with celecoxib for advanced pancreatic cancer. Proc Am Soc Clin Oncol 2003; 1502.
17. MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 2004; 5(9): 541-9.
18. Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 2005; 128(6): 1642-54.
19. Xiong HQ. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 2004; 54 (Suppl 1): S69-77.
20. Kopper L, Zalatnai A, Timar J. Genomics of pancreatic cancer: Does it make any improvement in diagnosis, prognosis and therapy? Pathol Oncol Res 2005; 11(2): 69-73.
21. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23(11): 2445-59.
22. Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II Trial. J Clin Oncol 2004; 22(13): 2610-6.
23. Li J, Kleeff J, Giese N et al. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol 2004; 25(1): 203-10.
24. Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002; 1(10): 777-83.
25. Herbst RS, Erlotinib (Tarceva): An update on the clinical trial program. Semin Oncol 2003; 30 (Suppl7): 34-46.
26. Morgan JA, Bukowsky RM, Xiong H et al. Preliminary report of a phase 1 study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, given in combination with gemcitabine to patients with advanced pancreatic cancer (abstract 788). Proc Am Soc Clin Oncol 22: 197 2003.
27. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc Am Soc Clin Oncol 2005, 1: 1.
28. Jimeno A, Rubio-Viqueira B, Amador ML et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res. 2005; 65(8): 3003-10.
29. Kindler HLAR, Lester E et al. Bevacizumab plus Gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2003; 1037.
30. Crane CH, Ellis LM, Abbruzzese JL et al. Phase I Trial of Bevacizumab (BV) with Concurrent Radiotherapy (RT) and Capecitabine (CAP) in Locally Advanced Pancreatic Adenocarcinoma (PA). Proc Am Soc Clin Oncol 2005; 23: 4033.
31. Khorana AA, Hu YC, Ryan CK et al. VEGF, Angiogenesis and Adjuvant Therapy Outcomes in Resected Pancreatic Cancer. Proc Am Soc Clin Oncol 2005; 23: 4032.
32. Bocci G, Danesi R, Marangoni G et al. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: An experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur J Pharmacol. 2004; 498(1-3): 9-18.
33. Schuch G, Kisker O, Atala A, Soker S. Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis. Angiogenesis 2002; 5(3): 181-90.
34. Hicklin DJ, Ellis LM. Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
35. Gasparini G, Longo R, Fanelli M et al. Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions. J Clin Oncol 2005; 23: 1295-1311.
36. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5(1): 119-27.
37. Adams J, Palombella VJ, Sausville EA et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
38. Aghajanian C, Soignet S, Dizon DS et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8: 2505-2511.
39. Shah SA, Potter MW, McDade TP et al: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82: 110-122.
40. Apama Mani, Edward P. Gelmann The Ubiquitin-Proteasome Pathway and its Role in Cancer. J Clin Oncol 2005; 21: 4776-4789.
41. Shapiro CL, Ramaswamy B, Young D, Lamb T et al. Phase I trial of bortezomib (Velcade™) in combination with paclitaxel in advanced solid tumor patients (pts) Proc Am Soc Clin Oncol 2005; 23: 3104.
42. Yeung B, Freeburg EN, Huang DT. Sinicrope Bortezomib FA (Velcade®) induces oxidative stress and apoptosis that are synergistically enhanced by a Bcl-2 inhibitor in human pancreatic cancer cells. Proc Am Soc Clin Oncol 2005; 23: 3161.